Superbug showdown: which drug combo wins?
NCT ID NCT07524920
First seen May 05, 2026 · Last updated Jun 23, 2026 · Updated 7 times
Summary
This study compares two different antibiotic combinations to see which works better at wiping out multi-drug resistant bacteria in adults. Sixty hospitalized patients will receive either meropenem plus colistin or imipenem/cilastatin plus tigecycline. Researchers will track lab results, symptoms, and side effects to find the safer, more effective option.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MDR BACTERIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
El-Demerdash hospital
Cairo, Egypt
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
antibiotic combinations (meropenem + colistin, or imipenem/cilastatin + tigecycline)
What this could lead to
If one combination works better, it could give doctors a more effective option to treat dangerous drug-resistant infections.
What could go wrong
This is a small early-stage trial with only 60 people, so results may not apply to everyone. Both combos can cause kidney or liver side effects.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.